Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) are increasingly used in the treatment of many tumor types, and durable responses can be observed in select populations. However, patients may exhibit significant immune-related adverse events (irAEs) that may lead to morbidity. There is limited information on whe...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Emma Titmuss, Irene S. Yu, Erin D. Pleasance, Laura M. Williamson, Karen Mungall, Andrew J. Mungall, Daniel J. Renouf, Richard Moore, Steven J. M. Jones, Marco A. Marra, Janessa J. Laskin, Kerry J. Savage
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2024-03-01
coleção:	Current Oncology
Assuntos:	immunotherapy immune-related adverse events genomics cancer immune checkpoint inhibitors
Acesso em linha:	https://www.mdpi.com/1718-7729/31/4/140
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!